Important legal notice
Contact   |   Search on EUROPA   
Security - Crime - Drugs
Security - Crime - Drugs - Combating crime through science
“To respond to the threat of bioterrorism by developing an effective vaccine and other countermeasures to protect against possible future anthrax attacks.”

The problem

Since the malicious release of anthrax spores through the US postal system in 2001, public authorities around the world have been making plans to cope with bio-terrorist attacks. Smallpox and anthrax are thought to pose the greatest threats. A proven vaccine for smallpox exists, but there is no safe and reliable inoculation against anthrax and current therapies would be ineffective against multi-drug resistant strains. European countries need to pool their resources to develop an effective response to terrorist attacks employing anthrax and other biological agents.

Anthrax‑EuroNet  Scientific shield against bioterror threats


Anthrax-EuroNet will bring together experts in public health, education, research and industry. The project aims to:

  • establish a research network that will accelerate the development and production of a vaccine and therapeutic countermeasures against anthrax bioterrorism
  • standardise and harmonise screening and testing protocols for vaccines and therapeutic measures
  • create a wider network (Euro-InfectNet) to provide Europe with a means of addressing the current and future needs for protecting its citizens against the threats of other high-risk bioterrorism agents and emerging diseases

Contribution to policy development:

  • Anthrax-EuroNet’s deliverables will contribute to the development of public health policies and future research priorities through both its networking and coordinated research activities
  • It could provide a model for similar research networks devoted to other high-risk infectious agents
  • The network could eventually be integrated into the proposed European Centre for Disease Control

Project deliverables

  • Kick-off workshop (June 2004) and workshops at the end of each year (January 2005, 2006, 2007)
  • Meetings on best practice for anthrax infection studies and immune response evaluation –
    June 2004
  • Report on data from validation studies – July 2006
  • Presentation of validation data – January 2006


  • Anthrax-EuroNet web platform – July 2004
  • Full-time public relations officer – ongoing
  • Provision of multimedia information packages on bioterrorism and civil protection for specific user groups – ongoing
  • Handbook and training on protocols and models for anthrax workers – Edition 1 (July 2005)/ Edition 2 (July 2006)
  • Conference on the threat of bioterrorism and European preparedness – January 2007

Technical information

Project acronym: Anthrax-EuroNet
Project’s official full title: Anthrax and Beyond - European research networking activities to develop safe products and policies to protect our citizens from the threat of anthrax attacks and other agents of bioterrorism
Research priority: 2.7. Issues related to civil protection (including biosecurity and protection against risks arising from terrorist attacks), and crisis management
Specific webpage:
Proposal/contract no: 503616
Start date: 01/01/2004
Kick off meeting: May 2004
Completion date: 31/12/2006
European Commission scientific officer: Paul Vossen (

Name: Max Planck Institute for Infection Biology
Abbreviated name: MPIIB
Address: 21/22 Schumannstrasse, 10117 Berlin
Country: Germany
Tel: +49 30 28460 502
Fax: +49 30 28460 503


Name: Health Protection Agency
Abbreviated name: HPA
Country: United Kingdom

Name: University of Hohenheim Institute of Environmental and Animal Hygiene
Abbreviated name: UHOH
Country: Germany

Name: Istituto Veneto di Medicina Molecolare
Abbreviated name: VIMM
Country: Italy 

Name: Istituto Zooprofilattico Sperimentale of Puglia and Basilicata
Abbreviated name: IZSPB
Country: Italy 

Name: Institut Pasteur - Laboratoire de Génétique Moléculaire des Toxines
Abbreviated name: IPTPB
Country: France